Polymorphs of suberoylanilide hydroxamic acid

摘要: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis neoplastic cells, inhibiting histone deacetylase (HDAC) by administration pharmaceutical compositions comprising potent HDAC inhibitors. oral bioavailability the active compounds in is surprisingly high. Moreover, unexpectedly give rise to high, therapeutically effective blood levels over an extended period time. further a safe, daily dosing regimen these compositions, which easy follow, and results amount inhibitors vivo. also novel Form I polymorph SAHA, characterized unique X-ray diffraction pattern Differential Scanning Calorimetry profile, as well crystalline structure.